DGAT Inhibitors
1 drugsAbout DGAT
Diacylglycerol acyltransferases (DGATs) are enzymes catalyzing the final step in triglyceride synthesis, essential for energy storage and lipid metabolism.
DGAT's role in triglyceride production makes it a potential drug target for metabolic disorders, though there is currently no genetic evidence directly linking it to specific diseases.
One FDA-approved drug, VASCEPA, targets DGAT as a small molecule for metabolic indications, developed by AMARIN PHARMS.
Top DGAT Drugs
AMARIN PHARMS is the only company with an approved DGAT-targeting drug.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in target validation.
DGAT Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DGAT, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
DGAT Clinical Trials 19 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DGAT. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 5 | 3 | 1 | 1 | 75% |
| Phase 3 | 6 | 2 | 1 | 3 | 67% |
| Phase 4 | 5 | 2 | 2 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DGAT Drug Approval Timeline (2012 - 2012)
VASCEPA was first approved in 2012 and remains the only approved drug.
The lack of recent approvals indicates potential saturation or challenges in developing new DGAT-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 18 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DGAT. A trial counts if an approved drug acting on DGAT is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.